In statement, BIO President and CEO Jim Greenwood said BIO is disappointed in reports from Atlanta that suggest Trade Ministers have failed to include 12 years of data exclusivity for biologics in Trans-Pacific Partnership agreement. BIO believes that 12 years of data exclusivity is a prerequisite to attract investment required to continue medical innovation and develop new biological cures and therapies. Failure of Asian-Pacific partners to agree to similar length of protection is short-sighted.